Causeway Therapeutics strategically targets a market with no existing FDA-approved drugs. By focusing on conditions like tennis elbow, where the standard of care is limited, they are creating a new therapeutic category rather than competing in a crowded space, giving them a unique market position.

Latigo Bio's commercial strategy is not to completely replace opioids but to relegate them to a last-resort option for rare and extreme situations. This pragmatic approach acknowledges that pain is treated multimodally and positions their Nav1.8 drug as the primary, safer alternative for the vast majority of patients, reducing overall opioid dependency.

When a competitor (Beijing) presented similar positive data for its BTK degrader, the CEO of Neurix viewed it as a positive reinforcement for the entire drug class. In a novel field, parallel success from independent companies de-risks the underlying biological mechanism for investors, partners, and clinicians.

Instead of a one-size-fits-all product, Latigo is creating two distinct Nav1.8 drugs. One offers rapid onset for acute pain (as a BID, or twice-a-day, drug), while the other is a once-daily (QD) formulation better suited for chronic pain management where adherence and convenience are key. This demonstrates a nuanced product-market fit strategy.

Luba Greenwood reframes competition in biotech as a positive force. When multiple companies pursue the same biological target, it validates the target's importance and accelerates discovery. This collaborative mindset benefits the entire field and, ultimately, patients, as the best and safest drug will prevail.

Venture investors aren't concerned when a portfolio company launches products that compete with their other investments. This is viewed as a positive signal of a massive winner—a company so dominant it expands into adjacent categories, which is the ultimate goal.

Protagonist believes its oral IL-23 blocker will not just compete with existing injectables but will capture a new market. They target the over 50% of eligible patients who currently take no therapy due to a dislike of injections or the safety profiles of other oral options, thereby expanding the total addressable market.

The significant challenges Vertex faces in collecting stem cells for its Casgevy therapy represent a key vulnerability. This manufacturing hurdle could allow competitors, such as Beam Therapeutics, to capture the market if their therapies offer a gentler and more efficient cell collection and manufacturing process.

Beyond converting patients from existing injectable therapies, the company's core growth strategy for its oral IL-23 drug is to capture the 50%+ of eligible patients who currently refuse treatment altogether because they dislike injections. This transforms the strategy from market share capture to market creation.